|
市場調查報告書
癌症診斷的技術革新：技術進歩、成長機會、未來的市場觀察
Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook
|
癌症診斷的技術革新：技術進歩、成長機會、未來的市場觀察 是由出版商Business Insights在2009年10月所出版的。
這份英文市場調查報告書包含141 pages 價格從美金3835起跳。
高齢化的成長、高科技醫療機器的開發中、癌症診斷領域在世界的市場上逐漸的擴大中。體外診斷或是影像物理療法的開發逐漸增多、醫師或是患者都追求更有效的治療方法。
報告書內容包括：癌症診斷領域的最新技術革新動向的統整、影像診斷及細胞診、分子診斷、基因體學等各種技術的動向和同業界中所面臨的課題。內容綱要摘記如下:
實施概要
第1章 概要
第2章 影像診斷的技術革新
第3章 分子診斷的技術革新
- 摘要
- 介紹
- DNA基因及染色體
- 免疫檢查及生物標記
- 表觀基因組學
- 微陣列
- 分子診斷的臨床應用的相關概要
第4章 基因體學的技術革新
- 摘要
- 介紹
- 家族性癌症
- 治療的反應
- FDA、EMEA及PGx的製品標示
- 附帶診斷
第5章 癌症診斷部門的課題
- 摘要
- 介紹
- 補貼的財源
- 新興市場
- 製薬公司和學術機關的提攜
- 研究開發
- 合併收買
第6章 競爭環境
- 摘要
- 介紹
- Abbot Diagnostics
- Affymetrix
- Beckman Coulter
- Becton Dickinson
- Bio-Rad Laboratories
- Gen-Probe
- Johnson & Johnson
- Luminex
- Nanogen
- Roche Diagnostics
- Siemens Healthcare Diagnostics
- Sysmex
- 未來動向
第7章 附錄
圖表
Abstract
Despite public policy measures to prevent cancer, such as tobacco control and
vaccination against HPV, cancer is sure to remain a significant public health
problem throughout the 21st century. Indeed, the global demographic shift
towards an ageing population and the spread of high tech modern medicine
throughout the emerging economies of Asia and (maybe later) Africa, will
expand the market for cancer diagnostics globally. Major developments are
likely in both the IVD market and in imaging-based modalities, like computed
tomography, with the emphasis being upon the personalized medicine approach,
where demand will come from physicians, patients and payors - all of whom
want more effective treatments and value for money. ' Innovations in Oncology
Diagnostics' is a new report published by Business Insights that analyzes the
latest innovations in oncology diagnostics and identifies the most exciting
new technologies and trends, ranging from body imaging and cytology to
molecular diagnostics and pharmacogenomics. This report also identifies the
key challenges facing innovative diagnostics companies.
Table of Contents
Executive summary
- Setting the scene
- Innovations in diagnostic imaging
- Innovations in molecular diagnostics
- Innovations in pharmacogenomics
- Challenges in the oncology diagnostics sector
- Competitive landscape
Chapter 1 Setting the scene
- Summary
- Introduction
- Cancer facts, current and projected
- History of oncology diagnostics
- Elements of a cancer diagnosis
- Pathology
- Oncology diagnostics market
Chapter 2 Innovations in diagnostic imaging
- Summary
- Introduction
- Body imaging
- Overview
- X-ray
- Computed tomography
- Lung cancer
- Colon cancer
- Others
- Ultrasound
- Magnetic resonance imaging
- Nuclear medicine - PET & SPECT
- Case study
- Cytology
- Overview
- Flow cytometry
- Case study
- Cervical screening
- Cytogenetics
Chapter 3 Innovations in molecular diagnostics
- Summary
- Introduction
- DNA, genes and chromosomes
- Fluorescence in situ hybridization (FISH)
- PCR and variants
- Case study
- Immunoassays and biomarkers
- Case study
- Ovarian cancer
- PSA testing
- Other areas of research
- Epigenomics
- Microarrays
- Comparative genomic hybridization (CGH)
- Case study
- Overview of clinical applications of molecular diagnostics
Chapter 4 Innovations in pharmacogenomics
- Summary
- Introduction
- Familial cancer
- Breast cancer
- Colon cancer
- Melanoma
- Case study
- Response to therapy
- Cytochrome P450 variants
- HER2 overexpression
- The FDA, EMEA and PGx labeling
- Case study
- TheraScreen: KRAS
- BioTheranostics: Breast cancer
- Clarient: Breast cancer
- Marker validation for erlotinib in lung cancer
- Companion diagnostics
Chapter 5 Challenges in the oncology diagnostics sector
- Summary
- Introduction
- Reimbursement funding
- Educated patients = educated decisions
- Regulation
- Pharmacoeconomics
- Emerging markets
- Partnerships between drug companies & academia
- Research & development
- Mergers & acquisitions
Chapter 6 Competitive landscape
- Summary
- Introduction
- Abbot Diagnostics
- Affymetrix
- Beckman Coulter
- Becton Dickinson
- Bio-Rad Laboratories
- Gen-Probe
- Johnson & Johnson (J&J)
- Ortho Clinical Diagnostics
- Luminex
- Nanogen
- Roche Diagnostics
- Siemens Healthcare Diagnostics
- Sysmex
- Future perspectives in the oncology diagnostics market
- Science
- Infrastructure
- Adoption of innovation
- Companion diagnostics
Chapter 7 Appendix
List of Figures
- Figure 1.1: Leading sites of new cancer US, 2009
- Figure 1.2: Leading sites of new cancer in developing countries, 2007
- Figure 1.3: Information required by oncologist pre/post diagnosis
- Figure 1.4: Oncology diagnostics forecasts ($bn), 2007-14
- Figure 2.5: Example of the use of 3D tomosynthesis imaging
- Figure 2.6: Number of CT scans in the US, 1995-2008
- Figure 2.7: Women having mammograms (%) in the US, 2004*
- Figure 2.8: Global flow cytometry market forecast ($bn), 2008-14
- Figure 3.9: IV diagnostics market forecast ($bn), 2007-2014)
- Figure 3.10: Use of biomarkers
- Figure 3.11: Obstacles to biomarker development
- Figure 3.12: US 5-year survival (%) for ovarian cancer at time of diagnosis
- Figure 4.13: Myriad: Molecular diagnostics sales ($m), 2005-09
- Figure 4.14: Number of biologics regulated by CDER that have existing PGx
information
- Figure 4.15: Herceptin therapy cost ($) per patient relative to HER2
testing
- Figure 5.16: Decline in S&P global sector indices (%), 12 months to
December 2008
- Figure 5.17: IV diagnostics risk-based classification
- Figure 5.18: FDA validated biomarkers by therapeutic area, September 2009
- Figure 5.19: Roche Diagnostics regional sales (CHFm), 2008
- Figure 5.20: Leading diagnostic firms increase in R&D spend (%) y-o-y, 2008
List of Tables
- Table 1.1: WHO cancer mortality forecasts by region (' 000), 2008-30
- Table 1.2: In vitro diagnostics market forecast ($bn), 2008-14
- Table 2.3: Overview of imaging systems
- Table 2.4: Mortality reduction (%) attributed to FOBT screening, 1985-96
- Table 2.5: Organ radiation data from various clinical studies
- Table 3.6: Extensively investigated cancer biomarkers
- Table 3.7: Market potential for Epigenomics' cancer specialty tests
- Table 4.8: Absent/incomplete efficacy (%) of drugs by therapeutic class
- Table 5.9: Leading M&A deals in the diagnostics industry ($m), 2009
- Table 6.10: Sales for the leading innovative oncology diagnostics
companies ($m), 2006-08
- Table 6.11: Beckman Coulter R&D investment ($m), 2004-08
- Table 6.12: Bio-Rad sales ($bn) 2004-2008
- Table 6.13: Roche Diagnostics sales by division (CHFm), H109
- Table 6.14: Major recent Dx-Rx partnerships
|
